Letter to the Editor

EPCA-2: A highly specific serum marker for prostate cancer

In 2007, Leman et al. published an apparently highly-promising new prostate cancer biomarker, early prostate cancer antigen-2 (EPCA-2) [1]. In my letter to Clinical Biochemistry [2], I criticized this biomarker and concluded that this marker may represent false discovery. These authors have now retracted this paper [3], citing that their original findings may be unreliable.

References


Eletherios P. Diamandis
Mount Sinai Hospital and University Health Network, Canada
Division of Clinical Biochemistry, Department of Laboratory Medicine & Pathobiology, University of Toronto, Canada
Mount Sinai Hospital, Joseph & Wolf Lebovic Ctr., 60 Murray St [Box 32]: Flr 6 - Rm L6-201, Toronto, ON, MST 3L9, Canada.
Fax: +1 416 619 5521.
E-mail address: ediamandis@mtsinai.on.ca.

15 February 2012